Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24608
Abstract: The introduction of bortezomib has revolutionized the treatment of multiple myeloma (MM) and significantly improved outcomes in MM patients. Similar to many other chemotherapeutic agents, there are numerous reports of bortezomib-induced cardiotoxicity. Furthermore, the FDA… read more here.
Keywords: ixazomib; induced cardiotoxicity; proteasome inhibitors; treatment ... See more keywords